← All Authorities
United States

Myriad Genetics (Association for Molecular Pathology v)

569 US 576 (2013)
JurisdictionUnited States
Year2013
Statusunclear

Key Principle

Naturally occurring DNA segments are products of nature and are not patent-eligible under 35 USC §101; synthetically created complementary DNA (cDNA) is patent-eligible.

Area of Law

ip

Related Cases

Cantarella Bros Pty Ltd v Modena Trading Pty Ltd (2014) 254 CLR 337
Phonographic Performance Company of Australia Ltd v Commonwealth (2012) 246 CLR 561
Roadshow Films Pty Ltd v iiNet Ltd (2012) 248 CLR 42

Ask CommonBench about this case

Get a detailed analysis of Myriad Genetics (Association for Molecular Pathology v) and how it applies to your situation.

Explain Myriad Genetics (Association f...